Chimera Therapeutics ( NASDAQ: KYMR) reported data on the Phase 1 patient cohort of its KT-474 (IRAK4) drug and updated information on three cancer programs: KT-413 (IRAKIMiD), KT-333 (STAT3), and CT- 253 (MDM2).
KT-474 :
The company stated that Part C of its phase 1 study KT-474 was designed to confirm that pharmacokinetic/pharmacodynamic (PK/PD) and safety data previously demonstrated in healthy volunteers can be applied to patients with hidradenitis suppurativa (HS ) and atopic dermatitis. dermatitis will apply. Atopic dermatitis (AD), also known as eczema.
SG is a condition in which painful lumps appear under the skin, usually at the junctions of the skin, such as B. in the armpits and in the groin.
In patients, CT-474 demonstrated plasma pharmacokinetics in fraction C comparable to those in healthy subjects at MAD3. The agency reported that baseline levels of IRAK4 in skin lesions in HS and AD patients were almost twice as high as in healthy volunteers.
The added Kymera KT-474 showed IRAK4 knockdown in both blood and skin comparable to MAD3, with a maximum depletion of over 90%. The clearance of targets in both blood and skin was the same in patients with HS and AD.
According to the company, KT-474 is generally safe and well tolerated, with no serious drug-related side effects or infections.
In addition, Kymera announced that Sanofi ( NASDAQ:SNY ), which is working with Kymera to develop KT-474 (SAR444656) in addition to oncology and immuno-oncology, has committed to moving KT-474 (SAR444656) to Phase II. Trials are scheduled with preliminary trials in HS and AD. The first study is planned to start in 2023.
Oncological destructors: KT-333, KT-413, KT-253:
KT-333 : Kymera reported that KT-333 is being evaluated in a phase I trial in adult patients with relapsed and/or refractory lymphoma, leukemia, and solid tumors.
The company added that in humans, FC and PD converted to plasma as expected, with a maximum STAT3 knockdown of up to 86% after the first two doses and a maximum STAT3 depletion in PBMC after an average of 66%.
KT-413 : KT-413 is currently in Phase 1 trials given intravenously every 3 weeks in adult patients with relapsed and/or refractory B-cell non-Hodgkin's lymphoma.
The company added that plasma PK and PD were also translated as expected in DL1 and DL2 subjects, which showed dose-dependent clearance of IRAK4, Ikaros and Aiolos in PBMC, with 95/100% knockdown of Ikaros/Aiolos and 40% of IRAK4. In DL2.
KT-253 : Kymera noted that the FDA has approved an application to start trials of the drug, and the company plans to conduct a phase I trial of KT-253 in adult patients with solid and liquid tumors in 2023.
KYMR +32.69% to $34.30 in December 14 premarket.